Peptides and Compounds for Appetite Suppression
Scientific overview of compounds studied to reduce hunger and support lower caloric intake
Overview
This page explores compounds studied for appetite regulation and body-weight control, especially where central nervous system signaling or incretin pathways affect hunger and food intake.
Why people seek this topic
Readers usually seek this topic to compare obesity therapies, appetite-regulation pathways, and how evidence differs between investigational compounds and approved drugs.
Clinical context
This page organizes compounds by mechanism, evidence quality, and clinical maturity in the context of appetite suppression.
Research highlights
The strongest compounds in this category are approved incretin drugs, while investigational compounds remain lower-certainty options with less mature clinical support.
FAQs
What compounds are studied for appetite suppression?
The most commonly discussed compounds in this CMS for appetite suppression are semaglutide, tirzepatide, retatrutide, tesofensine, and SLU-PP-332.
Are all appetite-suppression compounds supported by the same evidence level?
No. Approved incretin therapies have much stronger human evidence than early investigational compounds.
Common peptides
Related comparisons
Recommended stacks
Monoamine Metabolic Stack
Metabolic Stack
Advanced Metabolic Stack
Metabolic Expenditure Stack
Related goals